soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine SELECT Trial

Researchers use GHRH fragments in studies examining growth hormone axis signaling and pulsatile endocrine regulation

Main menu Common skin conditions NEWS Join DermNet PRO Read more Quick links Created 2008

16 Cardiovascular outcomes The cardiovascular outcomes trial for tirzepatide, SURPASS-CVOT, is an active-comparator study versus dulaglutide 1.5 mg weekly and is ongoing

the inhibitory effect of alpha-MSH on production of inflammatory nitric oxide by lower bowel tissue was even greater [11]

Paragraph IV filing data, publicly available through the FDA Orange Book, gives PBM formulary teams early intelligence on generic entry timelines that manufacturers should be actively monitoring